ERBB2 and breast cancer: Triple-negative breast cancer is considered as the most immunogenic subtype of breast cancer, with a higher lymphocyte infiltration rate than HER2+ or HR+ tumors and thus regarded as a promising target for immunotherapies (Szekely et al., 2018).